Author

Sophie de Carné Trécesson

The Francis Crick InstituteORCID 0000-0002-9341-2586Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Claire E. PillsburyiD· 2 shared Julian DownwardiD· 2 shared Míriam Molina‐ArcasiD· 2 shared Mona TomaschkoiD· 2 shared Sareena RanaiD· 2 shared Alicia Alonso de la VegaiD· 1 shared Andrea de CastroiD· 1 shared Ania Mikolajczak· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Claire E. PillsburyORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Oncogenic RAS activity is linked to immune priming and adenosine-driven immune evasion in lung adenocarcinoma

Sophie de Carné Trécesson, Philip East, Claire E. Pillsbury, Mariana Silva dos Santos, Hongui Cha, Emma Colliver, Tegan Gilmore, Sareena Rana, Chris Moore, Scott Lighterness, Deborah R. Caswell, Jesse Boumelha, Mona Tomaschko, Romain Baer, Jim E. Eyles, , Julian Downward

This study links oncogenic RAS activity to immune priming and adenosine-driven immune evasion in lung adenocarcinoma, showing both pro-immunogenic and immunosuppressive effects.

bioRxiv · Nov 25, 2025 · PreprintCancer Biology

Leveraging death of drug-sensitive cancer cells to promote immune-mediated bystander killing of subclones of drug-resistant tumor cells

Mona Tomaschko, KangBo Ng, Christopher Moore, Claire E. Pillsbury, Sareena Rana, James Campbell, Saptaparna Mukherjee, Ania Mikolajczak, Panayiotis Anastasiou, Andrea de Castro, Alicia Alonso de la Vega, Sophie de Carné Trécesson, Nathan W. Goehring, Míriam Molina‐Arcas, Julian Downward

This study shows that targeting drug-sensitive cancer cells with G12Ci inhibitors and combining it with immune therapies can eliminate drug-resistant subclones through immune-mediated bystander killing.

bioRxiv · Oct 27, 2025 · PreprintCancer Biology